nach oben

International Journal of Public Health

Erschienen in:

03.10.2018 | Editorial

Seeking to introduce a pharmacoeconomics framework in Cyprus

verfasst von: Panagiotis Petrou

Erschienen in: International Journal of Public Health | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Excerpt

Health agencies face an array of profound challenges. Among them, the need to exert control over surging pharmaceutical expenditures is imperative (Dubois et al. 2000). If pharmaceutical expenditure is left unchecked, it threatens to jeopardise health systems’ fiscal sustainability and violate equity and solidarity, which are fundamental principles in health care provision. Pharmaceutical care has significantly contributed towards life’s expectancy increase and morbidity reduction, so health agencies must balance the need to keep affordable prices and give patients access to innovative products (Lichtenberg 2012). …

Dias S, Welton NJ, Sutton AJ et al (2013) Evidence synthesis for decision making 1: introduction. Med Decis Mak 33(5):597–606CrossRef

Dubois RW, Chawla AJ, Neslusan CA et al (2000) Explaining drug spending trends: does perception match reality? Health Aff 19(2):231–239CrossRef

Flume M, Bardou M, Capri S et al (2016) Feasibility and attractiveness of indication value-based pricing in key EU countries. J Mark Access Health Policy 4(1):1–6

Kantarjian M, Fojo T, Mathisen M et al (2013) Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol 31(28):3600–3604CrossRefPubMedPubMedCentral

Lichtenberg FR (2012) The contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001–2007. PharmacoEconomics 30(3):197–221CrossRefPubMed

Petrou P, Talias M (2013) A framework for applying health technology assessment in Cyprus: thoughts, success stories, and recommendation. Value Health Reg Issues 2:273–278CrossRefPubMed

Petrou P, Talias M (2014) A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer. Cost Eff Resour Alloc 12(12):1–11

Titel: Seeking to introduce a pharmacoeconomics framework in Cyprus
verfasst von: Panagiotis Petrou
Publikationsdatum: 03.10.2018
Verlag: Springer International Publishing
Erschienen in: International Journal of Public Health / Ausgabe 3/2019
Print ISSN: 1661-8556
Elektronische ISSN: 1661-8564
DOI: https://doi.org/10.1007/s00038-018-1161-z

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Current gaps in vaccination coverage: a need to improve prevention and care

Educational inequalities in Global Activity Limitation Indicator disability in 28 European Countries: Does the choice of survey matter?

Sex differences in mortality in migrants and the Swedish-born population: Is there a double survival advantage for immigrant women?

Roll-your-own cigarette use in Italy: sales and consumer profile—data from PASSI surveillance, 2015–2016

Health inequalities in terms of myocardial infarction and all-cause mortality: a study with German claims data covering 2006 to 2015

Feasibility of using respondent-driven sampling to recruit participants in superdiverse neighbourhoods for a general health survey